Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC

Graphical abstract

Saved in:
Bibliographic Details
Published inJournal of hepatology Vol. 66; no. 6; pp. 1166 - 1172
Main Authors Lencioni, Riccardo, Montal, Robert, Torres, Ferran, Park, Joong-Won, Decaens, Thomas, Raoul, Jean-Luc, Kudo, Masatoshi, Chang, Charissa, Ríos, José, Boige, Valerie, Assenat, Eric, Kang, Yoon-Koo, Lim, Ho-Yeong, Walters, Ian, Llovet, Josep M
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier B.V 01.06.2017
Elsevier Science Ltd
Elsevier
Subjects
Adult
Advanced BCLC
Aged
Aged, 80 and over
Alanine - analogs & derivatives
Alanine - therapeutic use
Antineoplastic Agents - therapeutic use
Assaigs clínics
Biomarkers
Brivanib, mRECIST
Carcinoma, hepatocellular
Carcinoma, Hepatocellular - drug therapy
Carcinoma, Hepatocellular - mortality
Carcinoma, Hepatocellular - pathology
Clinical trials
Càncer de fetge
Double-Blind Method
Female
Gastroenterology and Hepatology
Hepatocellular carcinoma
Human health and pathology
Humans
Hépatology and Gastroenterology
Kaplan-Meier Estimate
Life Sciences
Liver cancer
Liver Neoplasms - drug therapy
Liver Neoplasms - mortality
Liver Neoplasms - pathology
Male
Medical diagnosis
Middle Aged
Objective response
Patients
Prognosis
Pronòstic mèdic
Response evaluation criteria in solid tumours
Solid tumors
Surrogate end-point
Survival
Triazines - therapeutic use
Tumors
Young Adult
Carcinoma, hepatocellular
Liver cancer
Response evaluation criteria in solid tumours
Objective response
Brivanib, mRECIST
Advanced BCLC
Surrogate end-point
Carcinoma
mRECIST
Brivanib
hepatocellular
Online AccessGet full text

Cover

More Information
Summary:Graphical abstract
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-News-3
content type line 23
ISSN:0168-8278
1600-0641
DOI:10.1016/j.jhep.2017.01.012